Efficient in vitro lowering of carbonyl stress by the glyoxalase system in conventional glucose peritoneal dialysis fluid

Kidney International

Volumn 62, Issue 2, 2002, Pages 679-687

  Inagi, Reiko ^a,b   Miyata, Toshio ^a,b   Ueda, Yasuhiko ^a,b   Yoshino, Atsushi ^a,b   Nangaku, Masaomi ^a,b   Van Ypersele de Strihou, Charles ^a,b   Kurokawa, Kiyoshi ^a,b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Advanced glycation end product; Glutathione; Glyoxalase; Peritoneal dialysis; Reactive carbonyl compound

Indexed keywords

3 DEOXYGLUCOSONE; 3-DEOXYGLUCOSONE; AMINOGUANIDINE; DEOXYGLUCOSE; DIALYSIS FLUID; DRUG DERIVATIVE; GLUCOSE; GLUTATHIONE; GUANIDINE DERIVATIVE; LACTOYLGLUTATHIONE LYASE; METHYLGLYOXAL; CARBONYL DERIVATIVE; GLYOXAL; PERITONEAL DIALYSIS FLUID;

ANIMAL; ARTICLE; ARTIFICIAL MEMBRANE; C57BL MOUSE; CHO CELL; CHRONIC KIDNEY FAILURE; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HAMSTER; HUMAN; IN VITRO STUDY; METABOLISM; MOUSE; OXIDATIVE STRESS; PERITONEAL DIALYSIS; TRANSGENIC MOUSE; YEAST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INCUBATION TIME; NONHUMAN; PERITONEAL CAVITY; PERITONEUM CELL; PRIORITY JOURNAL; SUPERNATANT;

ANIMALS; CHO CELLS; CRICETINAE; DEOXYGLUCOSE; DIALYSIS SOLUTIONS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOSE; GLUTATHIONE; GUANIDINES; HUMANS; KIDNEY FAILURE, CHRONIC; LACTOYLGLUTATHIONE LYASE; MEMBRANES, ARTIFICIAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PYRUVALDEHYDE; YEASTS;

EID: 0035991616     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00488.x     Document Type: Article

References (35)

1. The peritoneal membrane in chronic peritoneal dialysis
2. Issues affecting the longevity of the continuous peritoneal dialysis therapy
3. Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes
4. 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis
5. In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis
6. Immunohistochemical detection of advanced glycosylation end products in the peritoneum and its possible pathophysiological role in CAPD
7. Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds
8. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modification in the peritoneum
9. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: Role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis
10. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis
11. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells
12. Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids
13. Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on advanced glycation end product and advanced lipoxidation end product formation
14. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: Involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors
15. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis
16. Glyoxalase activity in human red blood cells fractioned by age
17. Metabolism of 3-deoxyglucosone, an intermediate compound in the Maillard reaction, administered orally or intravenously to rats
18. Analysis of glyoxalase-I from normal and tumor tissue from human colon
19. In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions
20. Peritoneal dialysis solution biocompatibility: Inhibitory mechanisms and recent studies with bicarbonate-buffered solutions
21. Biocompatibility of new peritoneal dialysis solutions: Clinical experience
22. Icodextrin's effects on peritoneal transport
23. Amino acid-based peritoneal dialysis solutions
24. In vivo formation of a Schiff base of aminoguanidine with pyridoxal phosphate
25. First in vitro and in vivo experiences with stay-safe balance, a pH-neutral solution in a dual-chambered bag
26. epsi;-(carboxy-methyl) lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis
27. Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: Prospective crossover study with a three-compartment bag
28. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products
29. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels
30. Spectrophotometric assay for D-(-)-lactate in plasma
31. Neurocardiac toxicity of racemic D, L-lactate fluids
32. Ex vivo and in vivo gene transfer to the peritoneal membrane in a rat model
33. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics
34. Towards better dialysis compatibility: Advances in the biochemistry and pathophysiology of the peritoneal membranes
35. Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient